Analysts’ Viewpoint on Gemcitabine HCL Market Scenario
Increase in prevalence of different types of cancer such as ovarian, breast, pancreatic cancer, and non-small cell lung cancer (NSCLC) is expected to drive the global gemcitabine HCL market during the forecast period. According to the World Health Organization, 2.3 million women were diagnosed with breast cancer in 2020, and about 685,000 deaths occurred due to it. As of 2020, 7.8 million women were diagnosed with breast cancer in the last five years, making it the world’s most prevalent cancer. Increase in demand for cancer treatment such as chemotherapy is likely to drive the demand for gemcitabine injectable drugs. Additionally, the usage of gemcitabine for the treatment of SARS-CoV-2 infection has shown reduction in SARS-CoV-2 infection. Thus, rise in usage of gemcitabine fueled the global gemcitabine HCl market during the COVID-19 pandemic.
Gemcitabine is widely used as an antitumor agent in research labs and clinics. It is an antimetabolite and antineoplastic agent. Gemzar [gemcitabine hydrochloride (HCL)] is a nucleoside metabolic inhibitor that exhibits antitumor activity. It is soluble in water, mildly soluble in methanol, and insoluble in polar organic solvents and ethanol. In sterile form, it is administered intravenously. Vials contain either 200 mg or 1 g, 2 g, and 4 g of Gemzar. Increased awareness about cancer and patient support programs is also expected to propel the gemcitabine HCl market size from 2022 to 2031. For instance, Pancreatic Cancer Action Network hosts Pancreatic Cancer Awareness Month in November, every year, in order to donate and participate in fundraising and support legislation for research and other activities.
Request a sample to get extensive insights into the Gemcitabine HCL Market
Governments in developed and developing countries are conducting awareness campaigns in order to reduce mortality and morbidity rates and encourage people to go for early cancer diagnosis. This is expected to increase awareness about cancer diagnosis and treatment. For instance, Public Health England, an executive agency of the Department of Health in the U.K., started “Be Clear on Cancer” campaign, which aims to improve the rate of early cancer diagnosis. Several companies have started Patient Support Programs (PSPs) to reduce the cost of treatment. For instance, Roche's Blue Tree Program offers support to cancer patients during their treatment journey.
R&D strategies in the gemcitabine drug market for the last few years have been focusing primarily on improvement in treatment delivery and combination therapy. High unmet needs in this area and poor efficacy of current treatments in pancreatic cancer, which are mostly chemotherapies, have prompted developers to explore improved versions of branded gemcitabine agents.
NuCana Biomed’s Acelarin (NUC-1031), a reformulation of gemcitabine, is in late-stage clinical trial and has been engineered to overcome resistance mechanisms associated with the original drug. In 2019, Sun Pharma launched ready-to-infuse INFUGEM (gemcitabine in sodium chloride injection) in the U.S. INFUGEM, the first chemotherapy product that comes in a premixed, ready-to-infuse formulation, was approved by the U.S. Food and Drug Administration (FDA) in July 2018, in combination with other drugs, for the treatment of breast, ovarian, non-small cell lung cancers, and as a single agent to treat pancreatic cancer.
Request a custom report on Gemcitabine HCL Market
In terms of type, the global gemcitabine HCl market has been bifurcated into branded and generic. The generic segment held a dominant share of the market in 2021. The trend is projected to continue during the forecast period. This can be ascribed to low cost and efficacy of generic drugs and rise in number of cancer patients, which have led to an increase in demand for these products. Gemcitabine in combination with nab-paclitaxel has been reported to prolong survival in patients with metastatic pancreatic cancer.
Based on application, the global gemcitabine HCl market has been classified as pancreatic cancer, breast cancer, ovarian cancer, non-small cell lung carcinoma (NSCLC), and others. The pancreatic cancer segment is projected to dominate the global market during the forecast period, accounting for the major share of the market by 2031. Gemcitabine is the first line drug for the treatment of pancreatic cancer. Increase in demand for drugs to treat pancreatic cancer is expected to drive the segment.
In terms of end-user, the global gemcitabine HCl market has been divided as hospitals, cancer centers, and others. The hospitals segment is anticipated to dominate the global market during the forecast period. The segment is projected to account for a significant market share in 2031. The hospital infrastructure in emerging economies is developing at a significant pace, as several regional and national governments (for instance, Saudi Arabia) are encouraging private players to enter the healthcare services sector. Moreover, a large number of patients were treated in hospitals in the U.S. and Europe in 2021.
North America dominated the global gemcitabine HCl market, with more than 30% share in 2021. High adoption of generic drugs in the U.S., increasing approvals for new cancer drugs by the U.S. FDA, and rise in cancer treatments options in the U.S. and Canada contributed to North America's large market share.
Asia Pacific is also poised to register significant growth during the forecast period owing to large patient pool, increase in the incidence of cancer, aging population, rise in demand for generic cancer drugs, and export of generic drugs to Europe and North America.
The global gemcitabine HCl market is fragmented, with the presence of international and local players. Players are focused on adopting strategies such as acquisition & collaboration, geographic expansion, expansion of distribution channels, and R&D to enhance their share in the global gemcitabine HCl market. Key players operating in the global gemcitabine HCl market are Accord Healthcare, Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Mylan N.V., Fresenius SE & Co. KGaA, Pfizer, Inc., Eli Lilly and Company, Ingenus Pharmaceuticals, LLC., Cornerstone Pharmaceuticals, Inc. ADC Therapeutics SA, and Hikma Pharmaceuticals plc.
Each of these players has been profiled in the gemcitabine HCl market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
|
Attribute |
Detail |
|
Market Size Value in 2021 |
US$ 635.1 Mn |
|
Market Forecast Value in 2031 |
More than US$ 1.3 Bn |
|
Growth Rate (CAGR) |
7.8% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2020 |
|
Quantitative Units |
US$ Mn/Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global gemcitabine HCl market was valued at US$ 635.1 Mn in 2021
The global gemcitabine HCl market is projected to reach more than US$ 1.3 Bn by 2031
The global gemcitabine HCl market grew at a CAGR of 7.3% from 2017 to 2021
The global gemcitabine HCl market is anticipated to grow at a CAGR of 7.8% from 2022 to 2031
Rise in prevalence of various types of cancer, surge in demand for cancer treatment such as chemotherapy, and increase in cancer awareness & patient support programs
The pancreatic cancer segment accounted for more than 40% share of the global gemcitabine HCl market in 2021
North America is expected to account for major share of the global gemcitabine HCl market during the forecast period
Accord Healthcare, Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Mylan N.V., Fresenius SE & Co. KGaA, Pfizer, Inc., Eli Lilly and Company, Ingenus Pharmaceuticals, LLC., Cornerstone Pharmaceuticals, Inc., ADC Therapeutics SA, and Hikma Pharmaceuticals plc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Gemcitabine HCL Market
4. Market Overview
4.1. Introduction
4.1.1. Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Gemcitabine HCL Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Disease Prevalence & Incidence Rate globally with key countries
5.2. Regulatory Scenario by Region/globally
5.3. Pipeline Analysis
5.4. Key Mergers & Acquisitions
5.5. Pricing Analysis of Finished products
5.6. Overview of Manufacturers
5.7. Consumption of Gemcitabine HCl (Volume) per Region (2021)
5.8. Key Industry Developments (partnerships, mergers and acquisitions, etc.)
5.9. COVID 19 Impact Analysis
6. Global Gemcitabine HCL Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Type, 2017–2031
6.3.1. Branded
6.3.2. Generic
6.4. Market Attractiveness Analysis, by Type
7. Global Gemcitabine HCL Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Application, 2017–2031
7.3.1. Pancreatic Cancer
7.3.2. Breast Cancer
7.3.3. Ovarian Cancer
7.3.4. Non-small Cell Lung Carcinoma (NSCLC)
7.3.5. Others
7.4. Market Attractiveness Analysis, by Application
8. Global Gemcitabine HCL Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by End-user, 2017–2031
8.3.1. Hospitals
8.3.2. Cancer Centers
8.3.3. Others
8.4. Market Attractiveness Analysis, by End-user
9. Global Gemcitabine HCL Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Gemcitabine HCL Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Type, 2017–2031
10.2.1. Branded
10.2.2. Generic
10.3. Market Value Forecast, by Application, 2017–2031
10.3.1. Pancreatic Cancer
10.3.2. Breast Cancer
10.3.3. Ovarian Cancer
10.3.4. Non-small Cell Lung Carcinoma (NSCLC)
10.3.5. Others
10.4. Market Value Forecast, by End-user, 2017–2031
10.4.1. Hospitals
10.4.2. Cancer Centers
10.4.3. Others
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Type
10.6.2. By Application
10.6.3. By End-user
10.6.4. By Country
11. Europe Gemcitabine HCL Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type, 2017–2031
11.2.1. Branded
11.2.2. Generic
11.3. Market Value Forecast, by Application, 2017–2031
11.3.1. Pancreatic Cancer
11.3.2. Breast Cancer
11.3.3. Ovarian Cancer
11.3.4. Non-small Cell Lung Carcinoma (NSCLC)
11.3.5. Others
11.4. Market Value Forecast, by End-user, 2017–2031
11.4.1. Hospitals
11.4.2. Cancer Centers
11.4.3. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Type
11.6.2. By Application
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Gemcitabine HCL Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type, 2017–2031
12.2.1. Branded
12.2.2. Generic
12.3. Market Value Forecast, by Application, 2017–2031
12.3.1. Pancreatic Cancer
12.3.2. Breast Cancer
12.3.3. Ovarian Cancer
12.3.4. Non-small Cell Lung Carcinoma (NSCLC)
12.3.5. Others
12.4. Market Value Forecast, by End-user, 2017–2031
12.4.1. Hospitals
12.4.2. Cancer Centers
12.4.3. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Type
12.6.2. By Application
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Gemcitabine HCL Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type, 2017–2031
13.2.1. Branded
13.2.2. Generic
13.3. Market Value Forecast, by Application, 2017–2031
13.3.1. Pancreatic Cancer
13.3.2. Breast Cancer
13.3.3. Ovarian Cancer
13.3.4. Non-small Cell Lung Carcinoma (NSCLC)
13.3.5. Others
13.4. Market Value Forecast, by End-user, 2017–2031
13.4.1. Hospitals
13.4.2. Cancer Centers
13.4.3. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Type
13.6.2. By Application
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Gemcitabine HCL Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Type, 2017–2031
14.2.1. Branded
14.2.2. Generic
14.3. Market Value Forecast, by Application, 2017–2031
14.3.1. Pancreatic Cancer
14.3.2. Breast Cancer
14.3.3. Ovarian Cancer
14.3.4. Non-small Cell Lung Carcinoma (NSCLC)
14.3.5. Others
14.4. Market Value Forecast, by End-user, 2017–2031
14.4.1. Hospitals
14.4.2. Cancer Centers
14.4.3. Others
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Type
14.6.2. By Application
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (by tier and size of companies)
15.2. Market Share/Ranking Analysis, by Company, 2021
15.3. Company Profiles
15.3.1. Accord Healthcare
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Strategic Overview
15.3.2. Teva Pharmaceutical Industries Ltd.
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Strategic Overview
15.3.3. Dr. Reddy's Laboratories Ltd.
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Strategic Overview
15.3.4. Sun Pharmaceutical Industries Ltd.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Strategic Overview
15.3.5. Mylan N.V.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Strategic Overview
15.3.6. Fresenius SE & Co. KGaA
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Strategic Overview
15.3.7. Pfizer, Inc.
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Strategic Overview
15.3.8. Eli Lilly and Company
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Strategic Overview
15.3.9. Ingenus Pharmaceuticals, LLC.
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Strategic Overview
15.3.10. Cornerstone Pharmaceuticals, Inc.
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Strategic Overview
15.3.11. ADC Therapeutics SA
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Product Portfolio
15.3.11.3. SWOT Analysis
15.3.11.4. Strategic Overview
15.3.12. Hikma Pharmaceuticals plc
15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.12.2. Product Portfolio
15.3.12.3. SWOT Analysis
15.3.12.4. Strategic Overview
List of Tables
Table 01: Global Gemcitabine HCl Value (US$ Mn) Forecast, by Type, 2017–2031
Table 02: Global Gemcitabine HCl Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 03: Global Gemcitabine HCl Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 04: Global Gemcitabine HCl Value (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Gemcitabine HCl Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America Gemcitabine HCl Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 07: North America Gemcitabine HCl Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 08: North America Gemcitabine HCl Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 09: Europe Gemcitabine HCl Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe Gemcitabine HCl Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 11: Europe Gemcitabine HCl Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 12: Europe Gemcitabine HCl Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 13: Asia Pacific Gemcitabine HCl Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific Gemcitabine HCl Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 15: Asia Pacific Gemcitabine HCl Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 16: Asia Pacific Gemcitabine HCl Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 17: Latin America Gemcitabine HCl Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Latin America Gemcitabine HCl Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 19: Latin America Gemcitabine HCl Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 20: Latin America Gemcitabine HCl Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 21: Middle East & Africa Gemcitabine HCl Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Middle East & Africa Gemcitabine HCl Market Value (US$ Mn) Forecast, by Type , 2017–2031
Table 23: Middle East & Africa Gemcitabine HCl Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 24: Middle East & Africa Gemcitabine HCl Market Value (US$ Mn) Forecast, by End-user, 2017–2031
List of Figures
Figure 01: Global Gemcitabine HCl Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 02: Global Gemcitabine HCl Value Share, by Type, 2021
Figure 03: Global Gemcitabine HCl Value Share, by Application, 2021
Figure 04: Global Market Value Share, by End-user, 2021
Figure 05: Global Gemcitabine HCl Value Share, by Region, 2021
Figure 06: Global Gemcitabine HCl Value Share Analysis, by Type, 2021 and 2031
Figure 07: Global Gemcitabine HCl Attractiveness Analysis, by Type, 2022 and 2031
Figure 08: Global Gemcitabine HCl Revenue (US$ Mn) and Y-o-Y Growth (%), by Branded , 2017–2031
Figure 09: Global Gemcitabine HCl Revenue (US$ Mn) and Y-o-Y Growth (%), by Generic, 2017–2031
Figure 10: Global Gemcitabine HCl Market Value Share (%), by Application, 2021 and 2031
Figure 11: Global Gemcitabine HCl Market Attractiveness Analysis, by Application, 2022–2031
Figure 12: Global Gemcitabine HCl Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Pancreatic Cancer, 2017–2031
Figure 13: Global Gemcitabine HCl Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Ampoules, 2017–2031
Figure 14: Global Gemcitabine HCl Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Ovarian Cancer, 2017–2031
Figure 15: Global Gemcitabine HCl Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Non-small Cell Lung Carcinoma (NSCLC) , 2017–2031
Figure 16: Global Gemcitabine HCl Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2017–2031
Figure 17: Global Gemcitabine HCl Market Value Share Analysis, by End-user, 2021 and 2031
Figure 18: Global Gemcitabine HCl Market Attractiveness Analysis, by End-user, 2022–2031
Figure 19: Global Gemcitabine HCl Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Hospitals, 2017–2031
Figure 20: Global Gemcitabine HCl Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Cancer Centers, 2017–2031
Figure 21: Global Gemcitabine HCl Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2017–2031
Figure 22: Global Gemcitabine HCl Market Value Share, by Region, 2021 and 2031
Figure 23: Global Gemcitabine HCl Market Attractiveness Analysis, by Region, 2022–2031
Figure 24: North America Gemcitabine HCl Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031
Figure 25: North America Gemcitabine HCl Market Value Share, by Country, 2021–2031
Figure 26: North America Gemcitabine HCl Market Attractiveness Analysis, by Country, 2022–2031
Figure 27: North America Gemcitabine HCl Market Value Share Analysis, by Type, 2021 and 2031
Figure 28: North America Gemcitabine HCl Market Attractiveness Analysis, by Type, 2022–2031
Figure 29: North America Gemcitabine HCl Market Value Share Analysis, by Application, 2021 and 2031
Figure 30: North America Gemcitabine HCl Market Attractiveness Analysis, by Application, 2022–2031
Figure 31: North America Gemcitabine HCl Market Value Share Analysis, by End-user, 2021 and 2031
Figure 32: North America Gemcitabine HCl Market Attractiveness Analysis, by End-user, 2022–2031
Figure 33: Europe Gemcitabine HCl Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031
Figure 34: Europe Gemcitabine HCl Market Value Share, by Country/Sub-region, 2021–2031
Figure 35: Europe Gemcitabine HCl Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 36: Europe Gemcitabine HCl Market Value Share Analysis, by Type, 2021 and 2031
Figure 37: Europe Gemcitabine HCl Market Attractiveness Analysis, by Type, 2022–2031
Figure 38: Europe Gemcitabine HCl Market Value Share Analysis, by Application, 2021 and 2031
Figure 39: Europe Gemcitabine HCl Market Attractiveness Analysis, by Application, 2022–2031
Figure 40: Europe Gemcitabine HCl Market Value Share Analysis, by End-user, 2021 and 2031
Figure 41: Europe Gemcitabine HCl Market Attractiveness Analysis, by End-user, 2022–2031
Figure 42: Asia Pacific Gemcitabine HCl Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031
Figure 43: Asia Pacific Gemcitabine HCl Market Value Share, by Country/Sub-region, 2021–2031
Figure 44: Asia Pacific Gemcitabine HCl Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 45: Asia Pacific Gemcitabine HCl Market Value Share Analysis, by Type, 2021 and 2031
Figure 46: Asia Pacific Gemcitabine HCl Market Attractiveness Analysis, by Type, 2022–2031
Figure 47: Asia Pacific Gemcitabine HCl Market Value Share Analysis, by Application, 2021 and 2031
Figure 48: Asia Pacific Gemcitabine HCl Market Attractiveness Analysis, by Application, 2022–2031
Figure 49: Asia Pacific Gemcitabine HCl Market Value Share Analysis, by End-user, 2021 and 2031
Figure 50: Asia Pacific Gemcitabine HCl Market Attractiveness Analysis, by End-user, 2022–2031
Figure 51: Latin America Gemcitabine HCl Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031
Figure 52: Latin America Gemcitabine HCl Market Value Share, by Country/Sub-region, 2021–2031
Figure 53: Latin America Gemcitabine HCl Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 54: Latin America Gemcitabine HCl Market Value Share Analysis, by Type, 2021 and 2031
Figure 55: Latin America Gemcitabine HCl Market Attractiveness Analysis, by Type, 2022–2031
Figure 56: Latin America Gemcitabine HCl Market Value Share Analysis, by Application, 2021 and 2031
Figure 57: Latin America Gemcitabine HCl Market Attractiveness Analysis, by Application, 2022–2031
Figure 58: Latin America Gemcitabine HCl Market Value Share Analysis, by End-user, 2021 and 2031
Figure 59: Latin America Gemcitabine HCl Market Attractiveness Analysis, by End-user, 2022–2031
Figure 60: Middle East & Africa Gemcitabine HCl Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031
Figure 61: Middle East & Africa Gemcitabine HCl Market Value Share, by Country/Sub-region, 2021–2031
Figure 62: Middle East & Africa Gemcitabine HCl Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 63: Middle East & Africa Gemcitabine HCl Market Value Share Analysis, by Type, 2021 and 2031
Figure 64: Middle East & Africa Gemcitabine HCl Market Attractiveness Analysis, by Type, 2022–2031
Figure 65: Middle East & Africa Gemcitabine HCl Market Value Share Analysis, by Application, 2021 and 2031
Figure 66: Middle East & Africa Gemcitabine HCl Market Attractiveness Analysis, by Application, 2022–2031
Figure 67: Middle East & Africa Gemcitabine HCl Market Value Share Analysis, by End-user, 2021 and 2031
Figure 68: Middle East & Africa Gemcitabine HCl Market Attractiveness Analysis, by End-user, 2022–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Gemcitabine HCL Market
*86 figures and 60 tables includes